Obesity – Talk Bio

Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26

6 days ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, JPM26, Mike Doustdar, Novo Nordisk, Obesity, semaglutide, Wegovy pill

Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

2 weeks ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy

Obesity biotech Alveus raises ~$160M Series A to advance MariTide‑like GLP‑1/GIPR drug and amylin pipeline

2 weeks ago talkbio0Tagged * * New Rhein Healthcare Investors, * * Sanofi Capital, ALV-100, ALV-200, Alveus Therapeutics, Amylin, Andera Partners, Antagonist muscle action, GIPR gene, MariTide-like, Metabolic Diseases, Obesity, Omega Funds, Product containing glucagon-like peptide 1 receptor agonist (product), Series

Alveus Therapeutics; obesity biotech; $160 million Series A; ALV-100; MariTide-like; GLP-1 receptor agonist; GIPR antagonist; amylin; ALV-200; obesity drugs; metabolic diseases; Sanofi Capital; New Rhein Healthcare Investors; Andera Partners; Omega Funds

Eli Lilly Enters Second Collaboration with Nimbus Therapeutics in $55M Upfront Deal for Novel Oral Obesity Drug

2 weeks ago talkbio0Tagged eli lilly, Metabolic Diseases, Nimbus Therapeutics, Obesity, Oral treatment

Eli Lilly; Nimbus Therapeutics; obesity drug; $55M upfront; $1.3B deal; oral treatment; metabolic diseases

Arrowhead’s RNAi Obesity Programs ARO-INHBE and ARO-ALK7 Advance with Encouraging Phase 1/2a Data

2 weeks ago talkbio0Tagged ARO-ALK7, ARO-INHBE, Arrowhead Pharmaceuticals, Obesity, Phase 1/2a, RNA Interference, tirzepatide, Weight Loss, Zepbound

Arrowhead Pharmaceuticals; ARO-INHBE; ARO-ALK7; RNAi; obesity; Phase 1/2a; tirzepatide; Zepbound; weight loss

Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment

4 weeks ago talkbio0Tagged Approved, Glucagon-Like Peptide 1, Novo Nordisk, Obesity, oral semaglutide, United States Food and Drug Administration, Wegovy pill

Novo Nordisk; Wegovy pill; FDA approval; oral semaglutide; obesity treatment; GLP-1

FDA Approves Novo Nordisk’s Wegovy Pill as First Oral GLP-1 for Weight Management

4 weeks ago talkbio0Tagged Approved, Novo Nordisk, Obesity, oral semaglutide, United States Food and Drug Administration, Wegovy pill

Novo Nordisk; Wegovy pill; FDA approval; obesity treatment; oral semaglutide

Recent Biotech News: Altimmune’s Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback

1 month ago talkbio0Tagged Altimmune, China, Failed, IMPACT trial, Ipsen, MASH, Obesity, pemvidutide, Phase 2, United States Food and Drug Administration

Altimmune; pemvidutide; MASH; Phase 2b; IMPACT trial; FDA; China obesity; Ipsen; Phase 2 fail

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

1 month ago talkbio0Tagged Approved, Clinical Trials, Eli, Glucagon-Like Peptide 1, injectable incretins, national priority review voucher, Obesity, Oral cavity, orforglipron, Phase 3 trial, United States Food and Drug Administration, Wegovy, weight maintenance, Zepbound

Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial

Innovent’s Mazdutide Shows Promising Obesity Data in Adolescents; No Everest PCSK9 News

1 month ago talkbio0Tagged Adolescent (age group), China, Innovent, mazdutide, Obesity, Phase 1b, Weight Loss

Innovent; mazdutide; obesity; adolescents; Phase 1b; weight loss; China